Publications
Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn’s Disease: Meta-Analysis of Randomised Controlled Trials
Citation
Almradi A, Sedano R, Hogan M, Zou GY, MacDonald JK, Parker CE, Hanzel J, Crowley E, Singh S, D'Haens G, Sandborn WJ, Feagan BG, Ma C, Jairath V. Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials. J Crohns Colitis. 2022 Jun 24;16(5):717-736. doi: 10.1093/ecco-jcc/jjab194. PMID: 34758084.
Abstract
Background: Precision in estimating placebo rates is important for clinical trial design.
Aim: To quantify placebo rates across relevant endpoints in Crohn’s disease [CD] trials and identify the factors influencing these rates in a contemporary meta-analysis.
